Combination of dacarbazine and dimethylfumarate efficiently reduces melanoma lymph node metastasis

Journal of Investigative Dermatology

Volumn 130, Issue 4, 2010, Pages 1087-1094

  Valero, Teresa ^a   Steele, Silvia ^a   Neumüller, Karin ^a   Bracher, Andreas ^a   Niederleithner, Heide ^a   Pehamberger, Hubert ^a   Petzelbauer, Peter ^a   Loewe, Robert ^a  

^a Universitatsklinik fur Dermatologie   (Austria)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 2 MICROGLOBULIN; CD31 ANTIGEN; CXCL11 CHEMOKINE; CXCL2 CHEMOKINE; DACARBAZINE; FUMARIC ACID DIMETHYL ESTER; HOMEODOMAIN PROTEIN; MESSENGER RNA; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL CADHERIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER MODEL; CANCER SIZE; CELL MIGRATION; CELL MOTILITY; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; LYMPH NODE METASTASIS; LYMPH VESSEL; MELANOMA; MELANOMA CELL; METASTASIS INHIBITION; MONOTHERAPY; MOUSE; MULTIPLE CYCLE TREATMENT; NONHUMAN; PRIMARY TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; SENTINEL LYMPH NODE; TUMOR VASCULARIZATION; TUMOR XENOGRAFT;

EID: 77949540419     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2009.368     Document Type: Article

References (44)

1. Aggarwal BB (2004) Nuclear factor-kappa-B: the enemy within. Cancer Cell 6:203-208
2. Alley MC, Powis G, Appel PL et al. (1984) Activation and inactivation of cancer chemotherapeutic agents by rat hepatocytes cocultured with human tumor cell lines. Cancer Res 44:549-556
3. Balch CM, Buzaid AC, Soong SJ et al. (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635-3648
4. Cabioglu N, Yazici MS, Arun B et al. (2005) CCR7 and CXCR4 as novel biomarkers predicting axillary lymph node metastasis in T1 breast cancer. Clin Cancer Res 11:5686-5693
5. Carmeliet P, Jain RK (2000) Angiogenesis in cancer and other diseases. Nature 407:249-257
6. Chang CC, Liu Z, Vlad G et al. (2009) Ig-like transcript 3 regulates expression of proinflammatory cytokines and migration of activated T cells. J Immunol 182:5208-5216
7. Dadras SS, Lange-Asschenfeldt B, Velasco P et al. (2005) Tumor lymphan-giogenesis predicts melanoma metastasis to sentinel lymph nodes. Mod Pathol 18:1232-1242
8. Eggermont AM, Kirkwood JM (2004) Re-evaluating the role of dacarbazine in metastatic melanoma: what have we learned in 30 years? Eur J Cancer 40:1825-1836
9. Garbe C, Eigentler TK (2007) Diagnosis and treatment of cutaneous melanoma: state of the art 2006. Melanoma Res 17:117-127
10. Gerulath AH, Loo TL (1972) Mechanism of action of 5-(3,3-dimethyl-1- triazeno)imidazole-4-carboxamide in mammalian cells in culture. Biochem Pharmacol 21:2335-2343
11. Gesser B, Johansen C, Rasmussen MK et al. (2007) Dimethylfumarate specifically inhibits the mitogen and stress-activated kinases 1 and 2 (MSK1/2): possible role for its anti-psoriatic effect. J Invest Dermatol 127:2129-2137
12. Hanahan D, Weinberg RA (2000) The hallmarks of cancer. Cell 100:57-70
13. Hayward IP, Parsons PG (1984) Epigenetic effects of the methylating agent 5-(3-methyl-1-triazeno) imidazole-4-carboxamide in human melanoma cells. Aust J Exp Biol Med Sci 62(Part 5):597-606
14. He Y, Rajantie I, Ilmonen M et al. (2004) Preexisting lymphatic endothelium but not endothelial progenitor cells are essential for tumor lymphangio-genesis and lymphatic metastasis. Cancer Res 64:3737-3740
15. Heere-Ress E, Boehm J, Thallinger C et al. (2005) Thalidomide enhances the anti-tumor activity of standard chemotherapy in a human melanoma xenotransplantation model. J Invest Dermatol 125:201-206
16. Karin M (2006) Nuclear factor-kappaB in cancer development and progression. Nature 441:431-436
17. Katerinaki E, Evans GS, Lorigan PC et al. (2003) TNF-alpha increases human melanoma cell invasion and migration in vitro: the role of proteolytic enzymes. Br J Cancer 89:1123-1129
18. Kawada K, Sonoshita M, Sakashita H et al. (2004) Pivotal role of CXCR3 in melanoma cell metastasis to lymph nodes. Cancer Res 64:4010-4017
19. Khan MA, Andrews S, Ismail-Khan R et al. (2006) Overall and progression-free survival in metastatic melanoma: analysis of a single-institution database. Cancer Control 13:211-217
20. Lehmann JCU, Listopad JJ, Rentzsch CU et al. (2007) Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol 127:835-845
21. Liang WC, Wu X, Peale FV et al. (2006) Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J Biol Chem 281:951-961
22. Lin WW, Karin M (2007) A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 117:1175-1183
23. Loewe R, Valero T, Kremling S et al. (2006) Dimethylfumarate impairs melanoma growth and metastasis. Cancer Res 66:11888-11896
24. Loewe R, Holnthoner W, Groger M et al. (2002) Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol 168:4781-4787
25. Loewe R, Pillinger M, de Martin R et al. (2001) Dimethylfumarate inhibits tumor-necrosis-factor-induced CD62E expression in an NF-kappa B-dependent manner. J Invest Dermatol 117:1363-1368
26. Mansfield AS, Markovic SN (2009) Novel therapeutics for the treatment of metastatic melanoma. Future Oncol 5:543-557
27. Massi D, Puig S, Franchi A et al. (2006) Tumour lymphangiogenesis is a possible predictor of sentinel lymph node status in cutaneous melanoma: a case-control study. J Clin Pathol 59:166-173
28. Meili-Butz S, Niermann T, Fasler-Kan E et al. (2008) Dimethyl fumarate, a small molecule drug for psoriasis, inhibits nuclear factor-kappaB and reduces myocardial infarct size in rats. Eur J Pharmacol 586: 251-258
29. Mrowietz U, Altmeyer P, Bieber T et al. (2007) Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 5:716-717
30. Mueller BM, Romerdahl CA, Trent JM et al. (1991) Suppression of spontaneous melanoma metastasis in scid mice with an antibody to the epidermal growth-factor receptor. Cancer Res 51:2193-2198
31. Proost P, Mortier A, Loos T et al. (2007) Proteolytic processing of CXCL11 by CD13/aminopeptidase N impairs CXCR3 and CXCR7 binding and signaling and reduces lymphocyte and endothelial cell migration. Blood 110:37-44
32. Richmond A, Yang J, Su Y (2009) The good and the bad of chemokines/ chemokine receptors in melanoma. Pigment Cell Melanoma Res 22:175-186
33. Saunders PP, Schultz GA (1972) Role of 4-diazoimidazole-5-carboxamide in the action of the antitumor agent 5(4)-(3,3-dimethyl-1-triazeno) imidazole-4-(5)carboxamide in Bacillus subtilis. Biochem Pharmacol 21:2065-2076
34. Schilling S, Goelz S, Linker R et al. (2006) Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration. Clin Exp Immunol 145:101-107
35. Schmidt TJ, Ak M, Mrowietz U (2007) Reactivity of dimethyl fumarate and methylhydrogen fumarate towards glutathione and N-acetyl-l-cysteine-preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem 15:333-342
36. Shields JD, Emmett MS, Dunn DB et al. (2007) Chemokine-mediated migration of melanoma cells towards lymphatics-a mechanism contributing to metastasis. Oncogene 26:2997-3005
37. Soengas MS, Lowe SW (2003) Apoptosis and melanoma chemoresistance. Oncogene 22:3138-3151
38. Steeg PS (2006) Tumor metastasis: mechanistic insights and clinical challenges. Nat Med 12:895-904
39. Tang W, Wang W, Zhang Y et al. (2009) Tumour necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced chemokine release in both TRAIL-resistant and TRAIL-sensitive cells via nuclear factor kappa B. FEBS J 276:581-593
40. Tsao H, Atkins MB, Sober AJ (2004) Management of cutaneous melanoma. N Engl J Med 351:998-1012
41. Vandermeeren M, Janssens S, Wouters H et al. (2001) Dimethylfumarate is an inhibitor of cytokine-induced nuclear translocation of NF-kappa B1, but not RelA in normal human dermal fibroblast cells. J Invest Dermatol 116:124-130
42. Yang J, Amiri KI, Burke JR et al. (2006) BMS-345541 targets inhibitor of \{kappa\}B kinase and induces apoptosis in melanoma: involvement of nuclear factor \{kappa\}B and mitochondria p. Clin Cancer Res 12:950-960
43. Yang JM, Richmond A (2001) Constitutive I kappa B kinase activity correlates with nuclear factor-kappa B activation in human melanoma cells. Cancer Res 61:4901-4909
44. Zhu N, Lalla R, Eves P et al. (2004) Melanoma cell migration is upregulated by tumour necrosis factor-alpha and suppressed by alpha-melanocyte-stimulating hormone. Br J Cancer 90:1457-1463